77 related articles for article (PubMed ID: 11938023)
1. Sulfonylurea receptor -1 (SUR1): genetic and metabolic evidences for a role in the susceptibility to type 2 diabetes mellitus.
Reis AF; Velho G
Diabetes Metab; 2002 Feb; 28(1):14-9. PubMed ID: 11938023
[TBL] [Abstract][Full Text] [Related]
2. Characterization of two novel forms of the rat sulphonylurea receptor SUR1A2 and SUR1BDelta31.
Gros L; Trapp S; Dabrowski M; Ashcroft FM; Bataille D; Blache P
Br J Pharmacol; 2002 Sep; 137(1):98-106. PubMed ID: 12183335
[TBL] [Abstract][Full Text] [Related]
3. KCNJ11, ABCC8 and TCF7L2 polymorphisms and the response to sulfonylurea treatment in patients with type 2 diabetes: a bioinformatics assessment.
Song J; Yang Y; Mauvais-Jarvis F; Wang YP; Niu T
BMC Med Genet; 2017 Jun; 18(1):64. PubMed ID: 28587604
[TBL] [Abstract][Full Text] [Related]
4. Candidate gene association study in type 2 diabetes indicates a role for genes involved in beta-cell function as well as insulin action.
Barroso I; Luan J; Middelberg RP; Harding AH; Franks PW; Jakes RW; Clayton D; Schafer AJ; O'Rahilly S; Wareham NJ
PLoS Biol; 2003 Oct; 1(1):E20. PubMed ID: 14551916
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and SAR of a novel Kir6.2/SUR1 channel opener scaffold identified by HTS.
Dodd CJ; Chronister KS; Rathnayake U; Parr LC; Li K; Chang S; Mi D; Days EL; Bauer JA; Cho HP; Boutaud O; Denton JS; Lindsley CW; Han C
Bioorg Med Chem Lett; 2023 May; 87():129256. PubMed ID: 36966977
[TBL] [Abstract][Full Text] [Related]
6. Genetic Variation at the Sulfonylurea Receptor, Type 2 Diabetes, and Coronary Heart Disease.
Emdin CA; Klarin D; Natarajan P; ; Florez JC; Kathiresan S; Khera AV
Diabetes; 2017 Aug; 66(8):2310-2315. PubMed ID: 28411266
[TBL] [Abstract][Full Text] [Related]
7. Paternal mutation of the sulfonylurea receptor (SUR1) gene and maternal loss of 11p15 imprinted genes lead to persistent hyperinsulinism in focal adenomatous hyperplasia.
Verkarre V; Fournet JC; de Lonlay P; Gross-Morand MS; Devillers M; Rahier J; Brunelle F; Robert JJ; Nihoul-Fékété C; Saudubray JM; Junien C
J Clin Invest; 1998 Oct; 102(7):1286-91. PubMed ID: 9769320
[TBL] [Abstract][Full Text] [Related]
8. ABCC8 (SUR1) and KCNJ11 (KIR6.2) mutations in persistent hyperinsulinemic hypoglycemia of infancy and evaluation of different therapeutic measures.
Darendeliler F; Fournet JC; Baş F; Junien C; Gross MS; Bundak R; Saka N; Günöz H
J Pediatr Endocrinol Metab; 2002; 15(7):993-1000. PubMed ID: 12199344
[TBL] [Abstract][Full Text] [Related]
9. Mutations in the sulonylurea receptor gene are associated with familial hyperinsulinism in Ashkenazi Jews.
Nestorowicz A; Wilson BA; Schoor KP; Inoue H; Glaser B; Landau H; Stanley CA; Thornton PS; Clement JP; Bryan J; Aguilar-Bryan L; Permutt MA
Hum Mol Genet; 1996 Nov; 5(11):1813-22. PubMed ID: 8923011
[TBL] [Abstract][Full Text] [Related]
10. Mutations in the genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) in diabetes mellitus and hyperinsulinism.
Gloyn AL; Siddiqui J; Ellard S
Hum Mutat; 2006 Mar; 27(3):220-31. PubMed ID: 16416420
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of action of a sulphonylurea receptor SUR1 mutation (F132L) that causes DEND syndrome.
Proks P; Shimomura K; Craig TJ; Girard CA; Ashcroft FM
Hum Mol Genet; 2007 Aug; 16(16):2011-9. PubMed ID: 17584766
[TBL] [Abstract][Full Text] [Related]
12. ABCC8 mutation allele frequency in the Ashkenazi Jewish population and risk of focal hyperinsulinemic hypoglycemia.
Glaser B; Blech I; Krakinovsky Y; Ekstein J; Gillis D; Mazor-Aronovitch K; Landau H; Abeliovich D
Genet Med; 2011 Oct; 13(10):891-4. PubMed ID: 21716120
[TBL] [Abstract][Full Text] [Related]
13. Neonates with symptomatic hyperinsulinemic hypoglycemia generate inappropriately low serum cortisol counterregulatory hormonal responses.
Hussain K; Hindmarsh P; Aynsley-Green A
J Clin Endocrinol Metab; 2003 Sep; 88(9):4342-7. PubMed ID: 12970308
[TBL] [Abstract][Full Text] [Related]
14. Determinants in Tailoring Antidiabetic Therapies: A Personalized Approach.
Rizvi AA; Abbas M; Verma S; Verma S; Khan A; Raza ST; Mahdi F
Glob Med Genet; 2022 Jun; 9(2):63-71. PubMed ID: 35707783
[TBL] [Abstract][Full Text] [Related]
15. Evidence That Substantia Nigra Pars Compacta Dopaminergic Neurons Are Selectively Vulnerable to Oxidative Stress Because They Are Highly Metabolically Active.
Ni A; Ernst C
Front Cell Neurosci; 2022; 16():826193. PubMed ID: 35308118
[TBL] [Abstract][Full Text] [Related]
16. Genetic underpinnings of cerebral edema in acute brain injury: an opportunity for pathway discovery.
Kirsch E; Szejko N; Falcone GJ
Neurosci Lett; 2020 Jun; 730():135046. PubMed ID: 32464484
[TBL] [Abstract][Full Text] [Related]
17. Practical combination therapy based on pathophysiology of type 2 diabetes.
Levin PA
Diabetes Metab Syndr Obes; 2016; 9():355-369. PubMed ID: 27826204
[TBL] [Abstract][Full Text] [Related]
18. CYP2C93 variant is associated with antidiabetes efficacy of gliclazide in Chinese type 2 diabetes patients.
Zeng W; Guo Y; Chen P; Liu Z; Chen D; Han C
J Diabetes Investig; 2016 Sep; 7(5):764-8. PubMed ID: 27181593
[TBL] [Abstract][Full Text] [Related]
19. A multiple kernel learning algorithm for drug-target interaction prediction.
Nascimento AC; Prudêncio RB; Costa IG
BMC Bioinformatics; 2016 Jan; 17():46. PubMed ID: 26801218
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietic stem cells exhibit a specific ABC transporter gene expression profile clearly distinct from other stem cells.
Tang L; Bergevoet SM; Gilissen C; de Witte T; Jansen JH; van der Reijden BA; Raymakers RA
BMC Pharmacol; 2010 Sep; 10():12. PubMed ID: 20836839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
